Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial source : Www.akerotx.com save search
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Published: 2021-07-08 (Crawled : 16:00) - akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -0.46%
H: 3.63%
C: 0.25%
phase 2 hepatitis efruxifermin trial phase 2b
Increased adiponectin following efruxifermin treatment is associatedwith improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NASH
Published: 2021-06-25 (Crawled : 16:00) - akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.11%
H: 0.35%
C: -2.92%
treatment nash liver efruxifermin trial
The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial
Published: 2021-06-21 (Crawled : 12:15) - akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.73%
H: 0.23%
C: -2.29%
treatment nash liver trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.